Effects of acute and chronic electroconvulsive shocks on glycogen synthase kinase 3β level and phosphorylation in Mice

Journal of ECT

Volumn 29, Issue 4, 2013, Pages 265-270

  Basar, Koray ^a   Eren Kocak, Emine ^a,b   Ozdemir, Hatice ^c   Ertugrul, Aygun ^a,b  

^a Gaza University School of Medicine   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c KIRIKKALE UNIVERSITY   (Turkey)

Author keywords

Antidepressants; Electroconvulsive Shock; Glycogen Synthase Kinase 3 ; Seizure

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORNEAL ELECTRODE; ELECTRIC SHOCK; ENZYME PHOSPHORYLATION; FRONTAL CORTEX; HIPPOCAMPUS; IMMUNOBLOTTING; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; ELECTROSHOCK; FRONTAL LOBE; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; MALE; MICE; MOOD DISORDERS; PHOSPHORYLATION; SERINE; TIME FACTORS;

EID: 84889087301     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0b013e318290f7ff     Document Type: Article

References (71)

1. O'Brien WT, Klein PS. Regulation of GSK-3 in patients with affective disorders. Biol Psychiatry. 2007;61:139-141.
2. Rowe MK, Wiest C, Chuang D. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev. 2007;31:920-931.
3. Chen G, Henter ID, Manji HK. Translational research in bipolar disorder: emerging insights from genetically based models. Mol Psychiatry. 2010;15:883-895.
4. Machado-Vieira R, Salvadore G, DiazGranados N, et al. New therapeutic targets for mood disorders. Sci World J. 2010;10:713-726.
5. Bennecib M, Gong CX, Gundke-Iqbal I, et al. Role of protein phosphatase-2A and-1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett. 2000;485:87-93.
6. Jope RS, Johnson GVW. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 2004;29:95-102.
7. Medina M, Wandosell F. Deconstructing GSK-3: the fine regulation of its activity. Int J Alzheimers Dis. 2011;2011:479249.
8. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A. 1996;93:8455-8459.
9. Stambolic V, Rucl L, Woodgett Jr. Lithium inhibits glycogen synthase kinase 3B and mimicks wingless activity in intact cells. Curr Biol. 1996;6:1664-1668.
10. Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophysic Res Com. 2001;280:720-725.
11. De Sarno P, Li X, Jope RS. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology. 2002;43:1158-1164.
12. Li X, Friedman AB, Zhu W, et al. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol Psychiatry. 2007;61:216-222.
13. O'Brien WT, Harper AD, Jove F, et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci. 2004;24:6791-6798.
14. Beaulieu JM, Sotnikova TD, Yao WD, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signalling cascade. Proc Natl Acad Sci U S A. 2004;101:5099-5104.
15. Silva R, Mesquita AR, Bessa J, et al. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3A. Neuroscience. 2008;152:656-669.
16. Prickaerts J, Moechars D, Cryns K, et al. Transgenic mice overexpressing glycogen synthase kinase 3A: A putative model of hyperactivity and mania. J Neurosci. 2006;26:9022-9029.
17. Ackermann TF, Kempe DS, Lang F, et al. Hyperactivity and enhanced curiosity of mice expressing PKB/SGK-resistant glycogen synthase kinase-3 (GSK-3). Cell Physiol Biochem. 2010;25:775-786.
18. Karege F, Perroud N, Burkhardt S, et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry. 2007;61:240-245.
19. Oh DH, Park YC, Kim SH. Increased glycogen synthase kinase-3beta mRNA level in the hippocampus of patients with major depression: A study using the Stanley neuropathology consortium integrative database. Psychiatry Investig. 2010;7:202-207.
20. Benedetti F, Serretti A, Colombo C, et al. A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age of onset and response to total sleep deprivation in bipolar depression. Neursoci Lett. 2004;368:123-126.
21. Benedetti F, Serretti A, Pontiggia A, et al. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta-50 T/C SNP. Neurosci Lett. 2005;376:51-55.
22. Zhang K, Yang C, Xu Y, et al. Genetic association of the interaction between the BDNF and GSK3B genes and major depressive disorder in a Chinese population. J Neural Transm. 2010;117:393-401.
23. Yang C, Xu Y, Sun N, et al. The combined effects of the BDNF and GSK3B genes modulate the relationship between negative life events and major depressive disorder. Brain Res. 2010;1355:1Y6.
24. Adli M, Hollinde DL, Stamm T, et al. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta-50T/C single nucleotide polymorphism. Biol Psychiatry. 2007;62:1295-1302.
25. Inkster B, Nichols TE, Saemann PG, et al. Association of GSK3A polymorphisms with brain structural changes in major depressive disorder. Arch Gen Psychiatry. 2009;66:721-728.
26. Inkster B, Nichols TE, Saemann PG, et al. Pathway-based approaches to imaging genetic association studies: Wnt signaling, GSK3beta substrates and major depression. NeuroImage. 2010;53:908-917.
27. Park SW, Phuong VT, Lee CH, et al. Effects of antipsychotic drugs on BDNF, GSK-3A, and A-catenin expression in rats subjected to immobilisation stress. Neurosci Res. 2011;71:335-340.
28. Chen YC, Tan QR, Dang W, et al. The effects of citalopram on chronic stressYinduced depressive-like behavior in rats through GSK3A/A-catenin activation in the medial prefrontal cortex. Brain Res Bull. 2012;88:338-344.
29. Szymanska M, Suska A, Budziszewska B, et al. Prenatal stress decreases glycogen synthase kinase-3 phosphorylation in the rat frontal cortex. Pharmacol Rep. 2009;61:612-620.
30. Kaidanovich-Beilin O, Milman A, Weizman A, et al. Rapid antidepressive-like activity of specific glycogen synthase kinase 3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol Psychiatry. 2004;55:781-784.
31. Gould TD, Einat H, Bhat R, et al. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol. 2004;7:387-390.
32. Rosa AO, Kaster MP, Binfaré RW, et al. Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1549-1556.
33. Du J, Wei Y, Liu L, et al. A kinesin signalling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci U S A. 2010;107:11573-11578.
34. Omata N, Chiu CT, Moya PR, et al. Lentivirally mediated GSK-3A silencing in the hippocampal dentate gyrus induces antidepressant-like effects in stressed mice. Int J Neuropsychopharmacol. 2011;14:711-717.
35. Shapira M, Licht A, Milman A, et al. Role of glycogen synthase kinase-3A in early depressive behavior induced by mild traumatic brain injury. Mol Cell Neurosci. 2007;34:571-577.
36. Li X, Zhu W, Roh MS, et al. In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology. 2004;29:1426-1431.
37. Roh MS, Eom TY, Zmijewska AA, et al. Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizors and imipramine. Biol Psychiatry. 2005;57:278-286.
38. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22:343-396.
39. Davidson Jr. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010;71(suppl E1):e04.
40. Roh MS, Kang UG, Shin SY, et al. Biphasic changes in the Ser9 phosphorylation of glycogen synthase kinase 3B after electroconvulsive shock in rat brain. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1Y5.
41. Kang UG, Roh MS, Jung JR, et al. Activation of protein kinase B (Akt) signalling after electroconvulsive shock in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:41-44.
42. Sutton LP, Rushlow WJ. The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling. Neuroscience. 2011;199:116-124.
43. Okamoto H, Voleti B, BanasrM, et al. Wnt2 expression and signalling is increased by different classes of antidepressant treatments. Biol Psychiatry. 2010;68:521-527.
44. Ghaemi SN. Why antidepressants are not antidepressant: STEP-BD, STAR D, and the return of neurotic depression. Bipolar Disord. 2008;10:957-968.
45. Dupuy JM, Ostacher MJ, Huffman J, et al. A critical review of pharmacotherapy for major depressive disorder. Int J Neuropsychopharmacol. 2011;14:1417-1431.
46. Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry. 1998;59(suppl 14):11-14.
47. Ishihara K, Sasa M. Mechanism underlying the therapeutic effects of electroconvulsive therapy (ECT) on depression. Jpn J Pharmacol. 1999;80:185-189.
48. D'Sa C, Duman RS. Antidepressants and neuroplasticity. Bipolar Disord. 2001;4:183-194.
49. Castrén E. Neurotrophic effects of antidepressant drugs. Curr Opin Pharmacol. 2004;4:58-64.
50. Duman RS, Monteggia LM. A neurotrophic model of stress-related mood disorders. Biol Psychiatry. 2006;59:1116-1127.
51. Jeon WJ, Kim SH, Seo MS, et al. Repeated electroconvulsive seizure induces c-Myc down-regulation and Bad inactivation in the rat frontal cortex. Exp Mol Med. 2008;40:435-444.
52. Kosten TA, Galloway MP, Duman RS, et al. Repeated unpredictable stress and antidepressants differentially regulate expression of the bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacol. 2008;33:1545-1558.
53. Hope BT, Kelz MB, Duman RS, et al. Chronic electroconvulsive seizure (ECS) treatment results in expression of a long-lasting AP-1 complex in brain with altered composition and characteristics. J Neurosci. 1994;14:4318-4328.
54. Tanis KQ, Duman RS, Newton SS. CREB binding and activity in brain: regional specificity and induction by electroconvulsive seizure. Biol Psychiatry. 2008;63:710-720.
55. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995;15:7539-7547.
56. Angelucci F, Aloe L, Jiménez-Vasquez P, et al. Electroconvulsive stimuli alter the regional concentrations of nerve growth factor, brain-derived neurotrophic factor, and glial cell-line derived neurotrophic factor in adult rat brain. J ECT. 2002;18:138-143.
57. Altar CA, Whitehead RE, Chen R, et al. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biol Psychiatry. 2003;54:703-709.
58. Stewart CA, Reid IC. Repeated ECS and fluoxetine administration have equivalent effects on hippocampal synaptic plasticity. Psychopharmacol. 2000;148:217-223.
59. Lamont SR, Paulls A, Stewart CA. Repeated electroconvulsive stimulation, but not antidepressant drugs, induces mossy fibre sprouting in the rat hippocampus. Brain Res. 2001;893:53-58.
60. Elfwing B, Bonefeld BE, Rosenberg R, et al. Differential expression of synaptic vesicle proteins after repeated electroconvulsive seizures in rat frontal cortex and hippocampus. Synapse. 2008;62:662-670.
61. Chen G, Madsen TM, Wegener G, et al. Repeated electroconvulsive seizures increase the total number of synapses in adult male rat hippocampus. Eur Neuropsychopharmacol. 2009;19:329-338.
62. Li W, Liu L, Liu Y, et al. Effects of electroconvulsive stimulation on long-term potentiation and synaptophysin in the hippocampus of rats with depressive behavior. J ECT. 2012;28:111-117.
63. Peineau S, Bradley C, Taghibiglou C, et al. The role of GSK-3 in synaptic plasticity. Br J Pharmacol. 2008;153:428-437.
64. Wada A. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3A, A-catenin, and neurotrophin cascades. J Pharmacol Sci. 2009;110:14-28.
65. Lange C, Mix E, Frahm J, et al. Small molecule GSK-3 inhibitors increase neurogenesis of human neural progenitor cells. Neurosci Lett. 2011;488:36-40.
66. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781-810.
67. Kang UG, Jeon WJ, Kim Y, et al. Transient activation of protein phosphatase 2A induced by electroconvulsive shock in the rat frontal cortex. Neurosci Lett. 2005;390:171-175.
68. Pap M, Cooper GM. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem. 1998;273:19929-19932.
69. Madsen TM, Newton SS, Eaton ME, et al. Chronic electroconvulsive seizure up-regulates beta-catenin expression in rat hippocampus: role in adult neurogenesis. Biol Psychiatry. 2003;54:1006-1014.
70. Mostany R, Valdizan EM, Pazos A. A role for nuclear beta-catenin in SNRI antidepressant-induced hippocampal cell proliferation. Neuropharmacology. 2008;55:18-26.
71. Gould TD, Einat H, O'Donnell KC, et al. beta-Catenin overexpression in the mouse brain phenocopies lithium sensitive behaviors. Neuropsychopharmacology. 2007;32:2173-2183.